No Data
No Data
Hesen Biotech acquires 14 branded pharmaceuticals from Celltrion, enriching product pipeline in 8 countries.
On June 28th, Heisen Biotech Co., Ltd. (Heisen Biotech) announced that it has officially completed the acquisition of the commercial rights of 14 branded products under the South Korean biopharmaceutical company Celltrion in multiple countries and regions in the Asia-Pacific region, and holds the marketing authorization holder (MAH) rights for these products in eight countries and regions including South Korea (excluding Nexinavir, Yidabio and Aiketuo), Singapore, Thailand, Australia, and Hong Kong, China. It is reported that this acquisition will enrich the company's product pipeline in eight countries and regions outside of mainland China and establish a more complete international supply chain and quality system.
Looking Into Loews's Recent Short Interest
Loews's (NYSE:L) short percent of float has fallen 8.99% since its last report. The company recently reported that it has 1.45 million shares sold short, which is 0.81% of all regular shares that are
Those Who Invested in Loews (NYSE:L) Five Years Ago Are up 39%
If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while
If EPS Growth Is Important To You, Loews (NYSE:L) Presents An Opportunity
Express News | Hanesbrands 13G Filing Shows Loews Corporation Reported A 7.8% Stake In The Co As Of June 5, 2024
Express News | Loews Corp Reports 7.8% Passive Stake in HanesBrands Inc as of June 5- SEC Filing
No Data